Abstract
Ultrasound targeted microbubble destruction (UTMD) has evolved as a novel system for non-invasive, organ- and tissuespecific drug and gene delivery. Initially developed as ultrasound contrast agents, microbubbles (MBs) have increasingly gained attention for their ability to directly deliver different classes of bioactive substances (e.g. genes, drugs, proteins, gene silencing constructs) to various organ systems and tumors. Bioactive substances can be attached to or incorporated in the microbubble shells. Applying ultrasound at their resonance frequency, microbubbles oscillate. When using higher ultrasound energies, oscillation amplitudes increase, finally resulting in microbubble destruction. This leads to increased capillary and cell membrane permeability in the immediate vicinity of the ruptured MBs, thus facilitating tissue and cell penetration of co-administered or loaded bioactive substances. Numerous proof of principle studies have been performed, demonstrating the broad potential of UTMD as a site-specific, non-invasive therapeutic tool, delivering microbubble payload to various target tissues and organ systems or facilitating uptake of bioactive substances into tissues or cells. This review focuses on current in vivo studies and therapeutic approaches of UTMD. Promising results give hope for future clinical applications of this novel non-viral vector system. Nevertheless, several limitations remain, which will also be discussed in this review article.
Keywords: Microbubble, UTMD, ultrasound, drug delivery, gene therapy, sonoporation, ultrasound contrast agent, triggered release
Current Pharmaceutical Design
Title:Microbubbles as a Vehicle for Gene and Drug Delivery: Current Clinical Implications and Future Perspectives
Volume: 18 Issue: 15
Author(s): Nicolas A Geis, Hugo A Katus and Raffi Bekeredjian
Affiliation:
Keywords: Microbubble, UTMD, ultrasound, drug delivery, gene therapy, sonoporation, ultrasound contrast agent, triggered release
Abstract: Ultrasound targeted microbubble destruction (UTMD) has evolved as a novel system for non-invasive, organ- and tissuespecific drug and gene delivery. Initially developed as ultrasound contrast agents, microbubbles (MBs) have increasingly gained attention for their ability to directly deliver different classes of bioactive substances (e.g. genes, drugs, proteins, gene silencing constructs) to various organ systems and tumors. Bioactive substances can be attached to or incorporated in the microbubble shells. Applying ultrasound at their resonance frequency, microbubbles oscillate. When using higher ultrasound energies, oscillation amplitudes increase, finally resulting in microbubble destruction. This leads to increased capillary and cell membrane permeability in the immediate vicinity of the ruptured MBs, thus facilitating tissue and cell penetration of co-administered or loaded bioactive substances. Numerous proof of principle studies have been performed, demonstrating the broad potential of UTMD as a site-specific, non-invasive therapeutic tool, delivering microbubble payload to various target tissues and organ systems or facilitating uptake of bioactive substances into tissues or cells. This review focuses on current in vivo studies and therapeutic approaches of UTMD. Promising results give hope for future clinical applications of this novel non-viral vector system. Nevertheless, several limitations remain, which will also be discussed in this review article.
Export Options
About this article
Cite this article as:
Geis A Nicolas, Katus A Hugo and Bekeredjian Raffi, Microbubbles as a Vehicle for Gene and Drug Delivery: Current Clinical Implications and Future Perspectives, Current Pharmaceutical Design 2012; 18 (15) . https://dx.doi.org/10.2174/138161212800099946
DOI https://dx.doi.org/10.2174/138161212800099946 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Proteomics and Mass Spectrometry: What Have We Learned About The Heart?
Current Cardiology Reviews Tetracyclines: Drugs with Huge Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Anti Citrullinated Protein Antibodies and Mechanism of Action of Common Disease Modifying Drugs - Insights in Pathomechanisms of Autoimmunity
Current Pharmaceutical Design Use of Biguanides and the Risk of Colorectal Cancer: A Register-Based Cohort Study
Current Drug Safety Diagnostics and Therapy of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitides
Current Pharmaceutical Design Optimal Dosing Design for Antibiotic Therapy in the Elderly: A Pharmacokinetic and Pharmacodynamic Perspective
Recent Patents on Anti-Infective Drug Discovery Inflammation Markers in Essential Hypertension
Medicinal Chemistry Dermatology and Global Health Meet Pharmacogenomics: Cutaneous Leishmaniasis
Current Pharmacogenomics and Personalized Medicine Enhanced Generation of Leukotriene B4 From Calcium Ionophore- Stimulated Rat Peritoneal Inflammatory Cells: A Possible Clinical Relevance
Current Drug Targets - Inflammation & Allergy Interaction of Drug or Food with Drug Transporters in Intestine and Liver
Current Drug Metabolism A179L, a New Viral Bcl2 Homolog Targeting Beclin 1 Autophagy Related Protein
Current Molecular Medicine Inhibition of Monoamine Neurotransmitter Transporters and Central Nervous System Stimulation Induced by Synthetic Local Anesthetics and Cocaine: A Comparative Review-Update
Current Medicinal Chemistry - Central Nervous System Agents Preparation and Evaluation of Polymeric Microparticles of Human Recombinant IL-1 Receptor Antagonist by Spray Drying
Drug Delivery Letters NMR Screening and Hit Validation in Fragment Based Drug Discovery
Current Topics in Medicinal Chemistry Impacts of Nanoparticles on Cardiovascular Diseases: Modulating Metabolism and Function of Endothelial Cells
Current Drug Metabolism A Review of Transdermal Drug Delivery Using Nano-Vesicular Carriers: Transfersomes
Recent Patents on Nanomedicine Impact of Renin-Angiotensin System in Hepatocellular Carcinoma
Current Cancer Drug Targets Population Pharmacokinetic Evaluation of a Fully Human IgG2 Monoclonal Antibody in Patients with Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) T Cell Replicative Senescence in Human Aging
Current Pharmaceutical Design Patent Selections
Recent Patents on DNA & Gene Sequences